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OPINION
Coxibs: can this class of drugs
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The sudden voluntary withdrawal of rofecoxib (Vioxx), a
“selective” cyclooxygenase 2 (Cox-2) inhibitor, by Merck
& Co on September 30, 2004, as a result of its adverse
cardiovascular effects (Couzin 2004), begs the question as
to whether this toxicity is a class effect. There is little doubt
that toxicity associated with a drug can permeate and have
a devastating effect on the clinical use of the entire class to
which the drug belongs, unless the nature of that toxicity is
clearly defined and characterized in a transparent fashion
within the scientific community. In this particular case, the
jury is still out. However, unless this class of drugs is used
appropriately and wisely, it will not survive.
Clinically, selective Cox-2 inhibitors and nonsteroidal
antiinflammatory drugs (NSAIDs) are used in the treatment
of arthritis, a degenerative disease of the joints. The
symptoms of arthritis can include pain, heat, redness,
swelling, stiffness, and/or restriction of movement. The most
common forms of arthritis are rheumatoid and osteoarthritis.
The former is a chronic inflammatory disease of joints
characterized by marked inflammation of the synovial
membrane and articular structures along with muscle
atrophy, whereas the pathology of the latter relates to loss
of articular cartilage, bone remodeling with possible
hypertrophy of the bone at margins, and changes in synovial
membrane. Arthritis is believed to be a major cause of
morbidity and disability in the population at large. The
discovery of Cox-2 inhibitors was considered an outright
breakthrough in the management of pain and inflammation
in arthritic patients without concomitant problems of
gastrointestinal disturbances and ulceration, but nothing is
that simple.
The beneficial effects of this class of drugs are believed
to be due to selective inhibition of the Cox enzyme. The
enzymes Cox-1 and Cox-2 are involved in the catabolism
of eicosanoids from arachidonic acid. Among these
ecosanoids are prostacyclin I2 (PGI2) and thromboxane A2
(TxA2). Both play a critical role in blood vessel function.
Where PGI2 is a substance that produces vasodilatation and
inhibits platelet aggregation, TxA2 is a potent vasoconstrictor
that promotes platelet aggregation (Catella-Lawson 2001).
In the past, Cox-1 was thought to be the constitutive enzyme
present in tissues such as platelets, vascular endothelial cells,
and gastric epithelial cells, whereas Cox-2 was the inducible
form; ie, its expression would be induced by
pathophysiological conditions, eg, inflammation. However,
evidence has accumulated to suggest that Cox-2 is an
enzyme primarily responsible for the synthesis of
PGI2,whereas Cox-1 is believed to be responsible for the
synthesis of TxA2 in platelets (Vinals et al 1997; Brock et al
1999; Catella-Lawson et al 1999; McAdam et al 1999). It
has also been suggested that Cox-2 has cardioprotective
properties (FitzGerald 2002). Thus, given that the selective
inhibition of Cox-2 may have been expected to result in
some detrimental effects on the cardiovascular system, it
would have been prudent to use these compounds cautiously
in patients with existing cardiovascular pathology.
However, no issue in clinical pharmacology is so
straightforward, and post-hoc analysis of data for coxibs,
rofecoxib, and celecoxib has provided contradictory
conclusions regarding cardiovascular safety. Evidence to
suggest that the use of coxibs could produce significant
detrimental cardiovascular effects was first brought to light
in the peer-reviewed medical literature by Murkherjee and
colleagues (2001). The authors analyzed data from
randomized clinical trials (VIGOR, CLASS trials, Study
085, and Study 090) for protective or hazardous effect
associated with the use of Cox-2 inhibitors. They concluded
that both rofecoxib (0.74%; p = 0.04) and celecoxib (0.8%;
p = 0.02) treatment produced a higher risk of unwanted
vascular events (eg, myocardial infarction) when compared
with placebo (0.52%) (Murkherjee et al 2001). In contrast
to the latter, a subsequent report by Konstam and colleagues
(2001) using a combined analysis of individual patient data
and assessing cardiovascular thrombotic events
(hemorrhagic, unknown deaths, nonfatal myocardial
infarction, and nonfatal strokes) in patients treated with
rofecoxib suggests there was no evidence of excess
cardiovascular events for rofecoxib compared with either
placebo (0.84; 95% CI: 0.51–1.38) or the non-naproxen
NSAIDs (0.79; 95% CI: 0.40–1.55) that were studied. The
authors of the latter study suggested that one reason for the
Murkherjee et al (2001) investigation to conclude that
Cox-2 inhibition would result in greater cardiovascular
thrombotic events was that absolute event rates across
different trials were employed for meta-analysis and, in theirVascular Health and Risk Management 2005:1(1) 6
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view, this is considerably less reliable (Konstam et al 2001).
As well, post-hoc analysis of data from CLASS and
SUCCESS trials by White and colleagues (2003) suggests
there is also no greater risk of cardiovascular thrombotic
events (1.06; 95% CI: 0.70–1.61; p = 0.79) associated with
celecoxib versus conventional NSAIDs or placebo (White
et al 2003).
A recent article published prior to the withdrawal of
rofecoxib, which reviewed the evidence for the risk of
thromboembolic events associated with Cox-2 inhibitors,
came to the conclusion that selective Cox-2 inhibitors should
be prescribed with caution and only in patients where such
therapy is warranted (Clark et al 2004). Many interesting
issues were addressed in this review in comparing and
contrasting the perceived basis for the adverse effects of
rofecoxib and celecoxib. One issue that was touched upon
was the concept of selectivity for Cox-2 versus Cox-1, and
one reason as to why celecoxib may have less adverse
cardiovascular effects was its lower selectivity for Cox-2
when compared with rofecoxib (Table 1), which is a
reasonable assumption. Should this be the case, then more
selective compounds may show a greater incidence of
adverse cardiovascular effects in patients at risk. It is also
interesting that the dose of rofecoxib employed in the latest
trial that resulted in its withdrawal from the market was a
lower one (25 mg daily) (Singh 2004) than in the VIGOR
trial (50 mg daily) (Bombardier et al 2000). The lower dose
would have been expected to produce less inhibition of
Cox-1, and this may have manifested in greater adverse
cardiovascular effects in patients prone to vascular problems.
More recently, a meta-analysis of pooled data from two
studies involving valdecoxib in patients who underwent
coronary artery bypass graft procedures suggests an
increased risk of myocardial infarction and stroke by more
than twofold. The relative risk being 2.19 (CI 1.19–4.03;
p = 0.01) (Liano 2004, online). It should be noted that the
latter analysis has not been peer-reviewed; however,
complete data from one of the trials reviewed were published
in a full paper last year. It indicates that the total number of
myocardial infarction, stroke, and death is fourfold higher
in the patients treated with Cox-2 inhibitors compared with
the placebo group (Ott et al 2003). Interestingly, analysis of
adverse effects individually; ie, deaths, cerebrovascular
disorders, and myocardial infarction in patients treated with
Cox-2 inhibitors compared with placebo indicates no
significance difference between the drug treatment versus
placebo group. Valdecoxib has a 30-fold selectivity for
Cox-2 versus Cox-1 (Table 1).
Admittedly, for a curious pharmacologist, the critical
question of whether the adverse cardiovascular effect of
coxibs is a class effect still must remain a mystery. Without
the clear cut evidence to suggest that the adverse effect is a
class effect in a population without vascular risk, selective
Cox-2 inhibitors still remain a viable option in the treatment
of rheumatoid arthritis and osteoarthritis in patients who
may have serious gastrointestinal problems with regards to
bleeding. A critical question is whether more selective
compounds that may offer better protection in the
gastrointestinal tract are more likely to produce a greater
incidence of cardiovascular and thrombotic events.
Moreover, will molecules that have a lower selectivity for
Cox-2 versus Cox-1 offer any gastrointestinal protection
on a long-term basis? Needless to say the use of these drugs
will require very careful monitoring in patients and selective
use may have to be implemented if we are to avoid losing
the entire class. It would appear that three simple reasons
may prevent this class of drugs from gaining wide
acceptance in mainstream clinical practice in the future and
eventually be responsible for the demise of the entire class.
They include: (1) convoluted and not very transparent
analysis of clinical data from trials; (2) lack of rigorous peer-
review of data and information from clinical trials; and
(3) inappropriate clinical use in a population of patients at
risk of vascular mortality.
Finally, it is perhaps rudimentary to suggest that the
survival of coxibs in clinical practice may very much depend
on pharmacokinetic and pharmacodynamic characteristics
of the molecule in question (Table 1). Simply put, the
combination of greater selectivity for the Cox-2 isozyme
and a prolonged half-life may not be the most favorable
profile that an agent needs to possess if it is to be used widely
and successfully against rheumatoid arthritis and
osteoarthritis in patients with vascular disorders. The
combination of high selectivity for Cox-2 and a prolonged
plasma half-life can result in the accumulation of the drug
in the body leading to enhanced inhibition of PGI2 formation,
and rampant elevation of TxA2 levels during the course of
Table 1 The ratio of IC50 for Cox-2, Cox-1, and plasma half-
life of four Coxibs
Drug names IC50 Cox-2 / Cox-1 t1/2 (hour)
Rofecoxib 35
a 9.9–17.5
b
Celecoxib 7.6
a 5.1–10.5
c
Valdecoxib 30a 7–8d
Etoricoxib 106
a 24.8
e
a Clark et al (2004); 
b Depre et al (2000); 
c Werner et al (2002); 
d Fenton et al
(2004); 
e Rodrigues et al (2003).Vascular Health and Risk Management 2005:1(1) 7
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therapy. Both are in turn expected to increase the likelihood
of adverse cardiovascular events such as stroke and
myocardial infarction.
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